Metastatic Castration-resistant Prostate Cancer Market Poised for Strong Growth by 2036, Due to the Launch of Drug Classes Such as Anti-B7-H3 ADC, PROTAC Protein Degrader, NTD AR Inhibitor, Radionuclide Therapy, and Several Others | DelveInsight

Anti-B7-H3 ADCPROTAC Protein DegraderNTD AR InhibitorPositive

AI Analysis

Summary

DelveInsight projects substantial growth in the metastatic castration-resistant prostate cancer market through 2036, driven by innovation including anti-B7-H3 ADC, PROTAC protein degraders, NTD AR inhibitors, and radionuclide therapies in late-stage clinical development.

Importance:2/10

Sentiment:

0.50

mCRPCprostate cancermarket analysisADCPROTACradionuclide therapylate-stage development

Related Companies

$IPIX $INTI

Read the original article

Published by PR Newswire Pharma on July 13, 2026 2:31 PM

Read Original